Clinical trial
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent…
NCT00217555 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00217555 |
|---|---|
| Title | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| Official title | Phase II Trial for the Treatment of Recurrent or Persistent Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With Gemcitabine and Topotecan |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, topotecan hydrochloride |
| Start date | Jul 1, 2002 |
| Primary completion | Feb 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 21, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: